Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBIT (2016 - 2025)

Historic EBIT for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$69.8 million.

  • Ocular Therapeutix's EBIT fell 3793.1% to -$69.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$270.0 million, marking a year-over-year decrease of 5718.62%. This contributed to the annual value of -$270.0 million for FY2025, which is 5718.68% down from last year.
  • Per Ocular Therapeutix's latest filing, its EBIT stood at -$69.8 million for Q4 2025, which was down 3793.1% from -$68.7 million recorded in Q3 2025.
  • Ocular Therapeutix's EBIT's 5-year high stood at -$17.8 million during Q1 2022, with a 5-year trough of -$69.8 million in Q4 2025.
  • Moreover, its 5-year median value for EBIT was -$21.1 million (2022), whereas its average is -$34.0 million.
  • Per our database at Business Quant, Ocular Therapeutix's EBIT surged by 1184.0% in 2022 and then plummeted by 15224.94% in 2024.
  • Ocular Therapeutix's EBIT (Quarter) stood at -$18.0 million in 2021, then fell by 7.27% to -$19.4 million in 2022, then fell by 3.56% to -$20.0 million in 2023, then plummeted by 152.25% to -$50.6 million in 2024, then plummeted by 37.93% to -$69.8 million in 2025.
  • Its EBIT was -$69.8 million in Q4 2025, compared to -$68.7 million in Q3 2025 and -$67.6 million in Q2 2025.